Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Prophylactic Effects of Ondansetron, Ramosetron, and Palonosetron on Patient-Controlled Analgesia Related Nausea and Vomiting After Urologic Laparoscopic Surgery

This study has been completed.
Information provided by (Responsible Party):
Hae Keum Kil, Yonsei University Identifier:
First received: July 22, 2010
Last updated: November 16, 2011
Last verified: November 2011
The aim of this prospective randomized controlled study was to compare the prophylactic effects of intravenous single dose of ondansetron, ramosetron, and palonosetron on PCA-related nausea and vomiting after urologic laparoscopic surgery.

Condition Intervention
Laparoscopic Marsupialization of Renal Cyst
Drug: Ondansetron
Drug: Ramosetron
Drug: Palonosetron
Drug: Normal saline inj

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: Prophylactic Effects of Ondansetron, Ramosetron, and Palonosetron on Patient-Controlled Analgesia Related Nausea and Vomiting After Urologic Laparoscopic Surgery

Resource links provided by NLM:

Further study details as provided by Hae Keum Kil, Yonsei University:

Primary Outcome Measures:
  • severity of nausea [ Time Frame: during 73 hours after surgery ]
  • the number of vomiting [ Time Frame: during 73 hours after surgery ]

Enrollment: 105
Study Start Date: August 2010
Study Completion Date: June 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ONSERAN Drug: Ondansetron
Ondansetron/single injection/4 mg/IV
Other Name: ONSERAN
Experimental: NASEA Drug: Ramosetron
Ramosetron HCl/single injection/0.3mg/IV
Other Name: NASEA
Experimental: ALOXI Drug: Palonosetron
Palonosetron HCl/single injection/0.075mg/IV
Other Name: ALOXI
Placebo Comparator: normal saline Drug: Normal saline inj
normal saline injection 2ml


Ages Eligible for Study:   20 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ASA I or II
  • Patients aged (20-65 yr) Undergoing Laparoscopic Nephrectomy
  • Patients who want a patient-controlled IV analgesia (IV-PCA)

Exclusion Criteria:

  • History of allergy or hypersensitivity to 5-HT3 antagonist
  • History of severe postoperative nausea/vomiting
  • Prolonged QT interval on preoperative EKG
  • Hypokalemia, Hypomagnesemia
  • Intestinal obstruction
  • Pregnant female or breast feeding mother
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01169805

Korea, Republic of
Severance Hospital, Yonsei University College of Medicine
Seoul, Korea, Republic of, 120-752
Sponsors and Collaborators
Yonsei University
  More Information

Responsible Party: Hae Keum Kil, Professor, Yonsei University Identifier: NCT01169805     History of Changes
Other Study ID Numbers: 4-2010-0176
Study First Received: July 22, 2010
Last Updated: November 16, 2011

Additional relevant MeSH terms:
Signs and Symptoms, Digestive
Signs and Symptoms
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Dermatologic Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Anti-Anxiety Agents processed this record on May 25, 2017